FDA published its quarterly report on ANDAs subject to priority review and those with a competitive generic therapy designation. The report provides data on those that are awaiting FDA application action at the end of each reporting quarter, as well as on the number of ANDAs approved in each of these categories during the reporting quarter.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
